Long-Term Kidney Outcomes in Paediatric Osteosarcoma Survivors: A 20-Year Multi-Centre Study
Authors:
- Christy Yuen-Kwan MakCMChristy Yuen-Kwan Mak
- Dennis Tak-Loi KuDKDennis Tak-Loi Ku
- Anthony Pak-Yin LiuALAnthony Pak-Yin Liu
- Vincent LeeVLVincent Lee
- Jeffrey Ping-Wa YauJYJeffrey Ping-Wa Yau
- Eric Chun-Ho FuEFEric Chun-Ho Fu
- Evelyn Ruoyun LuELEvelyn Ruoyun Lu
- Matthew Ming-Kong ShingMSMatthew Ming-Kong Shing
- Irene Yuk-Ying HoIHIrene Yuk-Ying Ho
- Will Wai-Lun PakWPWill Wai-Lun Pak
- Desmond Yat-Hin YapDYDesmond Yat-Hin Yap
- Alex Wing-Kwan LeungALAlex Wing-Kwan Leung
Open Access
Abstract
Background: The long-term kidney outcomes in paediatric osteosarcoma survivors treated with nephrotoxic chemotherapeutic agents are not well-described. Methods: We conducted a multi-centre retrospective cohort study and recruited paediatric osteosarcoma survivors who survived beyond 5 years from cancer diagnosis over a 20-year period. Chronic kidney disease (CKD) was defined as evidence of kidney impairment, chronic tubulopathy, and proteinuria upon last follow-up. Results: We included 89 patients (57% males) with a mean follow-up period of 14.9 years. A total of 42 subjects (47.2%) developed CKD, 28 of whom had CKD stage 1 with either chronic tubulopathy or proteinuria; 14 patients had CKD stage 2 (eGFR < 90 mL/min/1.73 m2), while two had CKD stage 3 (eGFR < 60 mL/min/1.73 m2). Chronic tubular dysfunction was reported in 34 patients (38%), with hypomagnesemia being the most common manifestation. Proteinuria and hypertension were infrequently observed, in 3% and 8% of cases, respectively. We found that a history of severe AKI and aminoglycoside exposure during the treatment course were significant risk factors for CKD, but the dose-dependent relationships between the development of CKD and cisplatin, ifosfamide, and methotrexate could not be demonstrated. Conclusions: CKD is prevalent among paediatric osteosarcoma survivors. Caution is needed when using multiple nephrotoxic agents at the same time, as this could increase the risk of CKD in the long run. Multi-disciplinary regular surveillance should be performed to identify and manage CKD early, including kidney function, electrolyte, and proteinuria monitoring.Keywords
This publication has 43 references indexed in Scilit:
- Chronic Kidney Disease or Hypertension After Childhood CancerJAMA Network Open, 2025
- Long‐term renal outcomes of children with cancers treated with platinum‐based chemotherapy: A retrospective chart analysisPediatric Blood & Cancer, 2024
- Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancerCochrane Database of Systematic Reviews, 2019
- Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillancePediatric Nephrology, 2017
- Aminoglycoside-induced nephrotoxicity in childrenPediatric Nephrology, 2016
- Achieving remission of proteinuria in childhood CKDPediatric Nephrology, 2016
- Late effects of chemotherapeutic agents on renal function in childhood cancer survivors: a review of the literatureIrish Journal of Medical Science (1971 -), 2016
- Antihypertensive Treatment and Renal Protection: the role of drugs inhibiting the renin-angiotensin-aldosterone systemHigh Blood Pressure & Cardiovascular Prevention, 2013
- Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dosePediatric Blood & Cancer, 2010
- Ifosfamide‐induced nephrotoxicity in 593 sarcoma patients: A report from the Late Effects Surveillance SystemPediatric Blood & Cancer, 2007